Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report

Lung adenocarcinoma is the most common pathological pattern of lung cancer. During the past decades, a number of targeted agents have been explored to treat advanced lung adenocarcinoma. In the present clinical practice, antagonists of the epidermal growth factor receptor (EGFR) and vascular endothe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Onco Targets Ther
Main Authors: Peng, Yanmei, Cui, Huijuan, Liu, Zhe, Liu, Daiwei, Liu, Fan, Song, Yazhong, Duan, Hua, Qiu, Yuqin, Li, Qiang
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2017
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5414636/
https://ncbi.nlm.nih.gov/pubmed/28490886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S130990
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados